Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Combined diphtheria, tetanus, acellular pertussis vaccine · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Combined diphtheria, tetanus, acellular pertussis vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP). Exclusion Criteria: * Use of any other investigational drug or vaccine 30 days preceding study vaccination. * Chronic administration of immunosuppressants. * A...
The combined diphtheria, tetanus, acellular pertussis vaccine is a vaccine designed to protect against three bacterial infections: diphtheria, tetanus, and acellular pertussis. It is developed by GSK plc and is given as a booster dose. The vaccine is in Phase 3 clinical development.
The combined diphtheria, tetanus, acellular pertussis vaccine is used for immunization against diphtheria, tetanus, and acellular pertussis. It is studied as a booster in people aged 10 years and older. The Phase 3 trial enrolled healthy volunteers in the United States.
GSK plc, which trades under the ticker GSK, is the developer of the combined diphtheria, tetanus, acellular pertussis vaccine. The company conducted the Phase 3 trial evaluating the vaccine as a booster compared with a licensed Td vaccine.
The combined diphtheria, tetanus, acellular pertussis vaccine is in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The vaccine is investigational and has not been approved by the FDA based on the available development information.
The combined diphtheria, tetanus, acellular pertussis vaccine was evaluated in the Phase 3 trial NCT00109330, titled A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine. The completed trial enrolled 4,116 participants aged 10 years and older in the United States and was randomized but uncontrolled.